Additional approval requirement in China pains drug industry

Between 50 and 60 new drugs cleared for clinical development in China face an additional layer of regulatory approval, which could further delay product approvals by 30 months, warns multinational big pharma trade group RDPAC.

Between 50 and 60 new drugs cleared for clinical development in China face an additional layer of regulatory approval, which could further delay product approvals by 30 months, warns multinational big pharma trade group RDPAC.

"Two applications, two approvals", the current regulatory process for imported drugs which most multinational drug makers use to get their innovative new products approved in China, seems set to get an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet